Capital Flow Monitor · Sponsors · CIK 1874298
Allotera Therapeutics, Inc.
4260 FOREST PARK AVE., SUITE 100, ST. LOUIS, MO, 63110 · 314-501-1968
Other Health Care · Corporation· inc. DELAWARE true
Fit score
—
Offering
$163.0M
Sold
$123.3M
% sold
75.6%
Investors
20
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-07-23 | D/A ·current | 506(b) | $163.0M | $123.3M | 75.6% | 20 | EDGAR ↗ |
| 2025-09-08 | D | 506(b) | $163.0M | $109.5M | 67.2% | 20 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
-
Niall O'Donnell — Director, St. Louis, MO
1 other raise
- Sparrow Pharmaceuticals, Inc. $61.8M of $121.4M · 50.9%
-
Bali Muralidhar — Director, St. Louis, MO
2 other raises
- AdvanCell, Inc. $218.3M of $315.0M · 69.3%
- SPRUCE BIOSCIENCES, INC. $50.0M of $50.0M · 100.0%
-
Peter Kiener — Director, St. Louis, MO
1 other raise
- Cue Biopharma, Inc. $50.0M of $50.0M · 100.0%
- Drew Dennison — Director, St. Louis, MO
- Kevin Li — Director, St. Louis, MO
- Bosun Hau — Director, St. Louis, MO
-
Matthew Cooper — Executive Officer, St. Louis, MO
5 other raises
- Polis Strategies Fund LLC - Series 5 $1.9M of $1.9M · 100.0%
- Enumera Molecular, Inc. $12.3M of $17.4M · 70.9%
- Polis Strategies Fund LLC - Series 1 $1.9M of $1.9M · 100.0%
- Polis MedTech Ventures LLC - Series 4 $900K of $900K · 100.0%
- Polis MedTech Ventures LLC - Series 3 $2.5M of $2.5M · 100.0%
- Ayman Kabakibi — Executive Officer, St. Louis, MO
- Natalie Mount — Director, St. Louis, MO
- Kumar Srinivasan — Executive Officer / Director, St. Louis, MO
- Cherry Thomas — Executive Officer, St. Louis, MO
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.